Biopharmaceutical Relevance of *In Vitro* Release and Skin Permeation Studies in Topical Product Development

**Sevgi Güngör**

*Istanbul University Faculty of Pharmacy*
*Department of Pharmaceutical Technology*
*Istanbul, Turkey*
Human Skin: an effective barrier

«Brick and mortar» model of the stratum corneum (horny layer) according to Elias (1981), to understand barrier function:
Topical Skin Delivery

**Key:** to deliver effective amount of drug into the right target site of the skin

Topical dosage forms are designed to deliver **therapeutically effective amount of drug** into the targeted skin layers for the treatment of skin diseases.
Skin Delivery: a sophisticated phenomenon!

Physicochemical features of drug substance

The excipients used in the formulation

The skin barrier and the state of disease
The Efficacy of Topical Semisolid Dosage Forms

**Keywords:** Diffusion and Partitioning

Topical dermatological products are mostly semisolid formulations including ointments, creams, lotions and gels.

The pharmacological action for a topical semisolid dermatological formulation depends on the efficacy of the **consecutive three main steps:**

- **Release and Diffusion**
  - the release of the drug molecule from the vehicle or delivery system (**diffusion and release**)

- **Diffusion**
  - the transport of the drug molecule through the stratum corneum (**diffusion**)

- **Partitioning**
  - the uptake of drug in viable epidermis and dermis (**partitioning**)

[Diagram showing the three main steps: Formulation, Stratum corneum, Viable epidermis, and Dermis, with an arrow indicating the direction of drug movement from Formulation to Dermis.]
However, **semisolid** dosage forms are **complex** formulations.

- They differ in excipient composition or dosage form (*gel versus cream, for instance*), amongst which the **partitioning** and **diffusion** of the drug substance **into and across the skin** may be altered.

- The rate of release of drug molecule from a semisolid topical formulation could be affected by its **physical and structural properties**.
The **physical and structural properties** of a topical semisolid dosage form depend upon various factors:

- Size and shape of dispersed particles
- Droplet size of the internal phase
- Physical state of drug substance (polymorphism)
- Interfacial tension between the phases
- Partition coefficient of the drug substance between the phases
- Rheology of the product
- Manufacturing process.
Measurement of drug release
The first step: drug release from the semisolid topical products

- The drug substance **must be released**, before it can diffuse into and become bioavailable in the skin.
- **The release** of a drug substance from the dosage form is crucial for efficacy of the topical dermatological semisolid products.
- The **measurement of drug release** from the formulation is important to topical drug product development for ensuring its quality.
**In vitro Release Test (IVRT)**

- *In vitro* release testing (IVRT) is used to monitor the release and diffusion of drug substances from semisolid dosage forms.
  - **The principle** is to determine the diffusion of the drug substance from a semisolid matrix across a membrane into appropriate receptor media.

- Although the release rate measured by IVRT may not reflect the in vivo fate of drug delivery, IVRT can determine
  - differences between release rates which may be occur due to formulation changes and
  - differences in various physicochemical properties of the drug product.
In vitro Permeation Test (IVPT)

- **IVPT** are also widely used for the development of topical dermatological products.

- The flux measurement following **IVPT** provide useful in vitro data during the development of a formulation for the selection of the best formulation.

- **IVPT** provide a more significant insight on the products in vivo performance.
IVRT & IVPT: Apparatus

IVRT Apparatus

Vertical diffusion cells

Immersion cells

USP Apparatus 4

USP <1724> Semisolid Drug Products-Performance Tests 2013
Apparatus: Franz Diffusion Cells

- Diffusion cells, such as **Vertical Franz Diffusion Cells** model is regarded as the most valid *in vitro* model for evaluating *in vitro* drug release and skin permeation from topical preparations.

- **Experimental set-up**
  - Receptor media selection: the solubility of drug substance in the receptor phase must be sufficient to maintain sink conditions.
  - Membrane selection: synthetic membranes act as inert support rather than a barrier (IVRT), human, porcine skin or artificial membranes resembling human skin, full thickness or dermatomed skin samples (IVPT)
  - Donor: dose application (finite/infinite vb)
  - Sampling periods and volume

- **Validation method**: mechanical calibration and performance verification testing

- **Data analysis**: Higuchi kinetic model, steady-state flux measurement
The most discriminant test conditions are recommended in an IVRT for semisolid dosage forms.

**Membrane:**
- **(IVRT):** Synthetic, reproducible compatibility assessment
- **IVRT:** human, porcine skin or artificial membranes, compatibility and integrity assessment

**Donor:**
- **(IVRT):** infinite dose, occluded, Preventing depletion of donor
- **(IVPT):** finite dose, occluded/non-occluded

**Sampling periods:**
- **(IVRT):** 4-6 h
- **(IVPT):** 1-24 h if necessary >24 h

**Receptor:**
sink conditions, 32°C

**Drug Transport:**
- **IVRT:** Limited lag time (<10%) steady state
- **IVPT:** Lag time, steady state

**Franz Diffusion Cells**
Recently, an integrated approach to qualify and validate an IVRT method for acyclovir cream 5% was performed.

- methodological, \textit{(individual parameters of IVRT)}
- and other critical components of the test system

\textit{(apparatus and laboratory qualification, HPLC method validation and IVRT method validation)}

IVRT & IVPT: Data Analysis

- The amount of drug released from the sample at different time intervals is quantified and calculated (Q):

\[
Q = \left( C_n V + \sum_{i=1}^{n-1} C_i S \right) / A
\]

- The cumulative amount of the drug released per surface area of the membrane (mcg/cm²)
- \( C_n \): the concentration of the compound (µg/mL) determined at nth sampling interval
- \( V \): the volume of individual Franz diffusion cell
- \( C_i \): the sum of concentrations of the compound (µg/mL) determined at sampling intervals 1 to n-1
- \( S \): the volume of sampling aliquot
- \( A \): the surface area

**IVRT**

- The **release rate** is the slope of the line described by \( Q \) values versus per square root of the time.
- Non-parametrical statistical method used for the comparison of the slopes
- Apparent amount <30 %
- Acceptance limit: 75-133.33%

**IVPT**

- The **flux** is the slope of the line described by \( Q \) values versus the time.
- Permeability coefficient (Kp) is calculated from donor drug concentration and calculated flux.
- Different statistical analysis used for the comparison of the slopes.
IVRT: Selection of membrane: filter interference

- Various synthetic membranes are used in IVRT to separate the donor and receptor compartment.
  - (e.g., cellulose acetate/nitrate/mixed ester, regenerated cellulose, or polytetrafluoroethylene)

- Synthetic membranes should
  - act as an inert support rather than barrier
  - provide least resistance to drug diffusion (non-rate limiting)

- The selection of appropriate membrane is crucial in the design of IVRT.
  - the membrane must be compatible with formulation and
  - no interference with the drug substance.
## IVRT: Case Study 1

<table>
<thead>
<tr>
<th>Compound</th>
<th>MW (g/mol)</th>
<th>Log P</th>
<th>Hydrogen acceptor group</th>
<th>Hydrogen donor group</th>
<th>Formulation Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir</td>
<td>225.21</td>
<td>-1.59</td>
<td>7</td>
<td>3</td>
<td>Cream</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>254.285</td>
<td>3.1</td>
<td>3</td>
<td>1</td>
<td>Gel</td>
</tr>
<tr>
<td>Flurbiprofen</td>
<td>244.261</td>
<td>4.16</td>
<td>2</td>
<td>1</td>
<td>Gel</td>
</tr>
</tbody>
</table>

Regenerated Cellulose Membrane  
Mixed Cellulose Membrane  
Cellulose Acetate Membrane

*Kocabaş Ö, Kahraman E. and Güngör S. unpublished data*
IVRT: Case Study 1

**Graphs:**
- **ACYCLOVIR:** Cumulative release of drug (mcg/cm²) vs. Sqt. Time (hour⁻¹/₂)
- **KETOPROFEN:** Cumulative release of drug (mcg/cm²) vs. Sqt. Time (hour⁻¹/₂)
- **FLURBIPROFEN:** Cumulative release of drug (mcg/cm²) vs. Sqt. Time (hour⁻¹/₂)

**Legend:**
- Regenerated Cellulose Membrane
- Mixed Cellulose Ester Membrane
- Cellulose Acetate Membrane

*Kocabaş Ö, Kahraman E. and Güngör S. unpublished data*
**IVRT: Case Study 1**

- **Acyclovir:**
  - The hydrogen bonds occur between hydroxyl and amine groups of the regenerated cellulose membrane and acceptor and donor groups in acyclovir. Therefore, the release of acyclovir across regenerated cellulose membrane was lower than those of other membranes.

- **Ketoprofen:**
  - The hydrogen bonds do not intensively form between the regenerated cellulose membrane and ketoprofen due to its less numbers of acceptor, donor groups. The release rate of ketoprofen across regenerated cellulose membrane is similar to those of other membranes.

- **Flurbiprofen:**
  - The hydrogen bonds could generate more strongly between hydroxyl groups in the regenerated cellulose membrane and, also fluorine atom in flurbiprofen in comparison with the oxygen atom of ketone in ketoprofen. This hydrogen bond is much more effective in compared to acceptor, donor groups of drug.
**IVRT: Case Study 2**

- **Regenerated Cellulose Membrane**
- **Mixed Cellulose Membrane**
- **Alclomethasone**
  - Hydrogene acceptor group: 5
  - Hydrogene donor group: 3
  - MW: 521,047 g/mol
  - Log P: 3.2

Kahraman E., Akdilek N. and Güngör S. unpublished data
Alclomethasone forms hydrogen bonds via only donor groups in the mixed membrane, whereas both of acceptor and donor groups in the drug are capable of formation of the hydrogen bonds, in the case of the regenerated cellulose membrane.

Thus, drug release through the regenerated cellulose membrane is lower than that of mixed cellulose membrane.

Kahraman E., Akdilek N. and Güngör S. unpublished data
Initially, **IVRT** has been recommended by the **FDA** to assess the similarity of a topical semisolid product following post-approval changes.

This guidance regulates the use of **IVRT** as evidence of product therapeutic and pharmaceutical sameness between the initially approved product and post-change product.
IVRT: Regulatory Perspectives (SUPAC-SS, 1997)

- IVRT is recommended to satisfy that consistent product performance will be performed after Level 2 changes:
  - changes in the components or composition (between 5 and 10% of excipients, with the total additive effect of all excipients changes being no more than 10%)
  - changes in manufacturing process (such as the rate of mixing, the rate of cooling, operating speeds and holding times)
  - changes in manufacturing equipment (different design or principle)
  - changes in batch size equipment (scale-up/scale-down of manufacture, more specifically changes in batch size beyond a factor of 10)
  - changes in manufacturing site

- IVRT can be used to requalify the product, if the ratio between the release rate for the post-change product over the release rate for the initially approved product falls within 75% to 133.3%. 
IVRT: Regulatory Perspectives

USP Chapter <1724> (2013)


- **IVRT** has been recognized as performance test by USP.
  - Describes the apparatus to be used for performance test of topical dosage forms
  - Describes details in developing **IVRT** with respect to the selection of key parameters
For the approval of a generic drug product, regulatory agencies mostly require clinical endpoint studies («gold standard») to validate the therapeutic equivalence of test product compared to reference product.

A waiver from the clinical endpoint studies is generally granted for solutions. However, the waiver option is not applied to semisolid dosage forms.

In recent years, FDA has published a few draft guidance in which the demonstration of IVRT and IVPT data has been recommended.
Topical Generic Products vs Reference (RLD)

Definition of Q1, Q2 & Q3

(Q1) Qualitative Similarity (Same components)
(Q2) Quantitative Similarity (Same amounts of same components)
(Q3) Similarity of the Formulation Microstructure (Same arrangement of matter)

Potential differences in Q3 demonstrate the physical properties of a semisolid dosage forms such as its rheological behavior and in vitro drug release pattern.
The parameters affecting microstructure (Q3) of a topical product

- Appearance
- Physicochemical features of the formulation (such as pH, specific gravity)
- The characteristics of drug substance (such as its polymorphic form, globule size distribution, particle size and its distribution)
- Rheological behavior of the semisolid formulation
- Drug release characteristics of the formulation

The microstructure similarity of the dosage form can be demonstrated based on the data obtained from well-designed IVRT method.
The workshop organized by Product Quality Research Institute (PQRI) and co-sponsored by AAPS, EUFEPS, FIP and USP.

- The Decision Tree Strawman of Topical Products for the assessment of bioequivalence was proposed.

- The decision tree was based on the Q1, Q2, and Q3 evaluation of the generic and RLD products.

- According to the proposal; If the generic and RLD products are qualitative (Q1) and quantitative equal (Q2), and Q3 equivalence can be shown by in vitro tests, such as IVPT and IVRT: clinical study may be waived.

The Strawman Decision Tree of Topical Products for the Assessment of Bioequivalence

Topical Drug Classification System- TCS

TCS is proposed by V. Shah and his co-workers as a classification system to justify biowaiver along with in vitro drug release characteristics of topical drug products.

- The classification is based on the qualitative (Q1) and quantitative composition (Q2), microstructure arrangements of matter (Q3) of a topical product and in vitro drug release (IVR).
Topical drug products are classified into 4 classes.

- **CLASS 1**: Q1, Q2 Same, Q3 Same
- **CLASS 2**: Q1, Q2 Same, Q3 Different
- **CLASS 3**: Q1, Q2 Different, Q3 Same
- **CLASS 4**: Q1, Q2 Different, Q3 Different

FDA Product-Specific Guidances for Generic Drug Development released for topical products in recent years.

FDA published a few draft guidance for some topical products including «acyclovir cream», «dapsone gel» and «ivermectin cream» «benzyl alcohol» have been to compare the bioequivalence of generics and RLD.

- It has been proposed that the combination of IVRT and IVPT using an *ex vivo* human skin model can be used with providing other supplementary specifications.
### IVRT & IVPT: Biowaiver options for Topical Semisolid Dosage Forms-FDA Draft Guidances

**Draft Guidance on Acyclovir**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA) and is not binding on requirements of the Office of Generic Drugs.

**Draft Guidance on Ivermectin**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA) and is not binding on requirements of the Office of Generic Drugs.

**Draft Guidance on Dapsone**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind the FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Draft Guidance on Benzyl Alcohol**

Table: Compound & Strengths

<table>
<thead>
<tr>
<th>Compound</th>
<th>Strength</th>
<th>Dosage Form</th>
<th>1st Option</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir</td>
<td>5.0%</td>
<td>Ointment</td>
<td>IVRT</td>
<td>2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cream</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ivermectin</td>
<td>1.0%</td>
<td>Cream</td>
<td>IVRT/IVPT+PKE</td>
<td>2016</td>
</tr>
<tr>
<td></td>
<td>5.0%</td>
<td>Gel</td>
<td>IVRT/IVPT+PKE</td>
<td>2016</td>
</tr>
<tr>
<td>Dapsone</td>
<td>7.5%</td>
<td>Gel</td>
<td>IVRT/IVPT+PKE</td>
<td>2017</td>
</tr>
<tr>
<td></td>
<td>10.0%</td>
<td>Cream</td>
<td>IVRT</td>
<td>2017</td>
</tr>
<tr>
<td>Benzyl alcohol</td>
<td>5.0%</td>
<td>Lotion</td>
<td>IVRT</td>
<td>2017</td>
</tr>
</tbody>
</table>
IVRT & IVPT: Biowaiver options for Topical Semisolid Dosage Forms- FDA Draft Guidances

- It is asked to demonstrate that Generic formulation (test) must provide Q1/Q2 criteria
  - the test and RLD formulations are qualitatively and quantitatively the same
- The test and RLD formulation must have the same physicochemical characteristics
- The test and RLD must exhibit the same drug release rate and permeation profile obtained from a validated IVRT and IVPT methods.
- The test and RLD products are bioequivalent based upon an acceptable in vitro pharmacokinetic (PK) study with one lot each of the test and RLD products (dapson, ivermectine).

- **Additional requirements that need to be presented:**
  - Comparison of **physical and structural similarity** for the test and RLD products should include the detailed physicochemical characterizations of test and RLD products.
  - The tests have to been performed in a minimum of three batches of the test and three batches of RLD.
Physicochemical characterizations for test and RLD products:

- Assessment of appearance
- Analysis of the polymorphic form of the drug substance in the topical product.
- Analysis of particle size distribution and crystal habit with representative microscopic images at multiple magnifications.
- Analysis of the rheological behavior which may be characterized using a rheometer that is appropriate for monitoring the non-Newtonian flow behavior of semi-solid dosage forms.

- A complete flow curve of shear stress (or viscosity) vs. shear rate should consist of multiple data points across the range of attainable shear rates, until low or high shear plateaus are identified.
- Yield stress values should be reported if the material tested exhibits plastic flow behavior.
Although, clinical endpoint studies must be carried out to prove the therapeutic equivalence, the draft guidance on micronized tretinoin gel (0.1% and 0.04%) indicates the importance of IVPT using dermatomed human skin to support pharmaceutical equivalence of the product.

When the systemic absorption is observed following topical application, PK endpoint studies could be used to prove the bioequivalence of the topical products, however, the quantification of drug substances is limited due to the low concentrations.

In addition to the PK evaluation, IVRT and IVPT should be also carried out (dapsone and ivermectine).
EMA: Concept paper on the development of a guideline on quality and equivalence of topical products, 2014

2 December 2014
EMA/CHMP/QWP/558185/2014
Committee for Medicinal Products for Human use (CHMP)

Concept paper on the development of a guideline on quality and equivalence of topical products

- EMA published a concept paper (EMA/CHMP/QWP/558185/2014)

Clinical trials are in principle necessary to demonstrate therapeutic equivalence, but other models may be used, if adequately validated.
In many cases, these other models have exhibited poor accuracy, sensitivity, reproducibility, in vitro in vivo correlation and have been unable to provide convincing evidence to predict the therapeutic equivalence.
The extended concept of pharmaceutical equivalence combined with additional measures of equivalence:

- **The quality data with the relevant reference medicinal product, including**
  - qualitative and quantitative composition
  - microstructure
  - physical properties
  - product performance and administration

- **The comparative data need to be representative, the test methods appropriate and validated, and**

- **Equivalence acceptance criteria should be adequate.**
  - however, critical evaluation has to be considered: (as stated in the EMA concept paper),
    - drugs with narrow therapeutic index,
    - drugs with significant side effects and with drugs that require additional safety requirements
Epiduo Gel (Adapalene 0.1% and Benzoyl peroxide 2.5%) (2007):

- IVPT data is presented as a part of the clinical development phase in new drug product application.
- In addition to PK data and clinical endpoint data, IVPT performed to prove the absence of significant differences between the dermal absorption of both drugs when administered in combination or as single product.

Tapin Cream (Lidocaine 25 mg/g and Prilocaine 25 mg/g) (2009):

- IVP across human skin of Tapin cream and the reference product (Emla) cream was compared. The accumulated amount of both drug substances (prilocaine and lidocaine) in the skin layers (stratum corneum, epidermis and dermis) was also measured following IVPT.
- The stability of the test product was also demonstrated with IVPT study in which the metabolite of prilocaine was added into the formulation and, it was shown that the accumulation of degradation product in the skin was not significantly different than that of the reference product.
- In addition, a pivotal, comparative clinical study was also performed.
Diclofenac-Ratiopharm 30 mg/g Gel Diclofenac AbZ30 mg/g Gel. (2018):
- In addition to new clinical data, **IVRT** and **IVPT data** were also submitted.

Pharmaceutical equivalence

According concept paper on the development of a guideline on “quality and equivalence of topical products (EMA/CHMP/QWP/558185/2014)”, pharmaceutical equivalence tests have been carried out comparing quality data of diclofenac sodium 30 mg/g gel with the relevant reference medicinal products, including qualitative and quantitative composition, microstructure, physical properties, product performance, and administration. The tests were performed with the EU product “Solaraze 3% gel” and also with the US product “Solaraze 3% gel”.

Diclofenac sodium 30 mg/g gel and the EU reference product “Solaraze 3% gel” are considered to be pharmaceutically equivalent since:
- The pharmaceutical form is the same.
- The active substance content is the same.
- All the excipients used in both products are qualitatively same and quantitatively similar.
- Quality characteristics are essentially the same. In particular, the applicant has provided compared in-vitro diffusion studies showing that the diffusion profiles of the generic and EU reference product are comparable. In addition, the submitted in-vitro skin permeation study shows a similar cumulative permeation profile between reference and EU reference product.
- Administration is the same.

In addition, the applicant submitted a supportive therapeutic equivalence study investigating the efficacy and safety of Diclofenac sodium 30 mg/g gel in comparison with placebo and with the US reference product (see Section III.3).
IVRT & IVPT: EMA Approach

- Compare to the FDA approach, **IVRT** and **IVPT** data without clinical studies for bioequivalence assessment of topical products in European countries has not been used to grant biowaiver.

- On the other hand, **IVRT** and **IVPT** has been accepted to evaluate the bioequivalence of topical products with other supplementary clinical studies.
Summary

- **IVRT** and **IVPT** has been considered a valuable tool in development of topical semisolid formulation.
  - to examine the effect of formulation components on the release of drug substance from different topical vehicles
  - to monitor the release rate and diffusion of drug products from semisolid dosage forms
  - to provide a scientific rationale for formulation selection.

- **IVRT** is used to assess the effect of following Level 2, scale up and post-approval changes (SUPAC-SS).

- **IVRT** is also accepted as a robust test for quality assessment of topical semisolid dosage forms (USP <1724>)

- **IVRT** and **IVPT** have been added into the FDA draft guidances to demonstrate BE of a few generic topical products.

- EMA concept paper also states as a tool **IVRT** and **IVPT** on topical drug development.
Conclusion

- Although understandable some limitations of both test, **IVRT** and **IVPT** are considered as robust tests to determine the topical product performance that contribute the efficacy (*bioavailability*) of the drug substances in the skin.

- As mentioned by Shah and co-workers, “*the well-established and time honored scientific principles*” that emphasize **IVRT** and **IVPT** methods, assist the application of these *in vitro methods* for the bioequivalence assessment of topical products.

- In recent years, the addition of **IVRT** and **IVPT** into the FDA draft guidances to validate bioequivalence of a few generic topical product, further boosts their application in future.
Acknowledgements:

- **Topical & Transdermal Research Group**
  
  Dr. Emine Kahraman  
  M.Sc. Pharm. Özge Kocabas  
  Pharm. Neriman Akdilek

- **Part of the presented experimental study was supported by Istanbul University Research Fund.**

Thank you for your attention!

e-mail: sgungor@istanbul.edu.tr